{"member_organisations": "", "identification_number": "368349831585-45", "fields_of_interest": "Public Health", "head_office_address": "Ole Maaloes Vej 3", "full_time_equivalent_fte": "0,75", "person_with_legal_responsibility": "Per Fischer", "inter_groups": "", "financial_year_start_date": "01/01/2017", "grants": "618931", "head_office_country": "Denmark", "eu_initiatives": "Mr Per Fischer, representative of MinervaX, would like to introduce the company to EC members and explore how our capabilities within our industry could be leveraged to achieve the goals within the European Commission.  \n \nMinervaX will be visiting Brussels to attend meetings with various EU Institutions and agencies to discuss feasibility of gaining support relating to the vaccine against Group B Streptococcus (GBS) that is currently undergoing clinical trials. \n \nHowever, our offerings are broad and deep, and we are also keen to gain insight from the EC members as to their perspectives on how MinervaX could bring value to ongoing and future EC needs in the Health Industry across a more comprehensive landscape.  \n \nMinervaX intends to apply under Horizon 2020 or other appropriate funding.", "organisation_name": "MinervaX", "belgium_office_post_code": "", "number_of_persons_involved": "1", "procurement": "", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "belgium_office_address": "", "subsection": "Companies & groups", "belgium_office_phone": "", "number_of_ep_accredited_persons": "", "overall_budget_turnover_as_a_range": "", "belgium_office_city": "", "persons_accredited_for_access_to_european_parliament_premises": "", "estimate_of_costs_absolute_amount": "", "registration_date": "21/05/2018", "website_address": "http://www.minervax.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Copenhagen", "membership": "", "head_office_post_code": "2200", "goals__remit": "MinervaX has advanced its GBS vaccine through clinical trials in 240 healthy adult women with very encouraging results and is the leading vaccine candidate currently in development. \n \nMinervaX wishes to advance the clinical program to the next stages and therefore would like to explore the availability of funding from the EU.", "industry_forums": "", "head_office_phone": "(+45)20 25 20 38", "level_of_interest": "global", "relevant_communication": "", "financial_year_end_date": "01/12/2017", "estimate_of_costs_as_a_range": "10000-24999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "ApS (Company)", "person_in_charge_of_eu_relations": "Per Fischer", "customers": "", "belgium_office_post_box": "", "position": "CEO"}